Adults receiving tirzepatide in the SURPASS trials had ... SURPASS trials enrolled adults with type 2 diabetes or overweight or obesity and without contraindications for GIP/GLP-1 use.

They share what is becoming an open secret: They tried for years to control their weight but are now taking the new obesity drugs manufactured by Eli Lilly and Novo Nordisk. Dr. Robert Califf ...

Jan. 27, 2025 — A study shows that patients with obesity and fatty liver-related cirrhosis who had bariatric (weight-loss) surgery significantly lowered their future ... Signposting Children to ...

Eli Lilly's tirzepatide has been shown to significantly cut cardiovascular risks in patients with obesity and a form of heart failure with few treatment options, in another big win for the GLP-1 ...

including obesity medicines. By the numbers, she was obese and hadn't been able to lose weight on her own. A nurse at the med spa offered her 16 weeks of compounded tirzepatide, which is the ...

The FDA has said it has agreed to reconsider its decision to prevent compounding pharmacies from producing and selling versions of Eli Lilly's diabetes and obesity drug tirzepatide. The US ...

Despite rising rates of diabetes and obesity, access to these medicines remain limited ... launch timing for Rybelsus or Wegovy in South Africa." After semaglutide, tirzepatide is probably the next ...

Support from readers like you keeps The Journal open. You are visiting us because we have something you value. Independent, unbiased news that tells the truth. Advertising revenue goes some way to ...

Mounjaro (tirzepatide) functions in a similar way ... for use as a treatment in Ireland for both type 2 diabetes and obesity. Maura Fay spoke to Dr Michael Crotty, clinical lead for obesity ...

Objective—Malabsorptive bariatric surgery (biliopancreatic diversion and biliointestinal bypass [BIBP]) reduces serum cholesterol levels more than restrictive surgery (adjustable gastric banding ...